Skip to Content
Merck
CN

PHR1624

Cisplatin

Pharmaceutical Secondary Standard; Certified Reference Material

Synonym(s):

cis-Diammineplatinum(II) dichloride, cis-Dichlorodiammine platinum(II), cis-Platinum(II) diammine dichloride, Cisplatin

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Linear Formula:
Pt(NH3)2Cl2
CAS Number:
15663-27-1
Molecular Weight:
300.05
NACRES:
NA.24
PubChem Substance ID:
329823516
UNSPSC Code:
41116107
EC Number:
239-733-8
MDL number:
MFCD00011623

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

LXZZYRPGZAFOLE-UHFFFAOYSA-L

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

SMILES string

N.N.Cl[Pt]Cl

grade

certified reference material, pharmaceutical secondary standard

agency

traceable to Ph. Eur. C2210000, traceable to USP 1134357

API family

cisplatin

CofA

current certificate can be downloaded

packaging

pkg of 200 mg

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

mp

270 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-30°C

Quality Level

300

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Cisplatin is an antineoplastic drug used for the treatment of cancer patients with a variety of different malignancies.

Application

Cisplatin may be used as an analytical reference standard for the determination of the analyte in plasma, cancer cell, and tumor samples by high-performance liquid chromatographic assay.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Biochem/physiol Actions

Potent platinum-based antineoplastic agent. Forms cytotoxic adducts with the DNA dinucleotide d(pGpG), inducing intrastrand cross-links.

Analysis Note

These secondary standards offer multi-traceability to the USP and EP primary standards, where they are available.

Other Notes

To see an example of a Certificate of Analysis for this material enter LRAB7778 in the slot below. This is an example certificate only and may not be the lot that you receive.
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

target_organs

Respiratory system

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Hazard Classifications

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Muta. 1B - Repr. 1B - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Storage Class

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A high-performance liquid chromatographic assay for determination of cisplatin in plasma, cancer cell, and tumor samples.
Lopez-Flores A, et al.
Journal of Pharmacological and Toxicological Methods, 52(3), 366-372 (2005)
Sonja Ludwig et al.
Cancer immunology, immunotherapy : CII, 68(7), 1133-1141 (2019-05-30)
Advanced oral squamous cell carcinomas (OSCC) have limited therapeutic options. Although immune therapies are emerging as a potentially effective alternative or adjunct to chemotherapies, the therapeutic efficacy of combination immune chemotherapies has yet to be determined. Using a 4-nitroquinolone-N-oxide (4NQO)
Sample handling for determination of free platinum in blood after cisplatin exposure.
Johnsson A, et al.
Cancer Chemotherapy and Pharmacology, 41(3), 248-251 (1997)
Adrián E Granada et al.
Molecular biology of the cell, 31(8), 845-857 (2020-02-13)
DNA-damaging chemotherapeutics are widely used in cancer treatments, but for solid tumors they often leave a residual tumor-cell population. Here we investigated how cellular states might affect the response of individual cells in a clonal population to cisplatin, a DNA-damaging
Jessica M Rusert et al.
Cancer research, 80(23), 5393-5407 (2020-10-14)
Medulloblastoma is among the most common malignant brain tumors in children. Recent studies have identified at least four subgroups of the disease that differ in terms of molecular characteristics and patient outcomes. Despite this heterogeneity, most patients with medulloblastoma receive
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service